BioLineRx Ltd. (TLV: BLRX)
Israel
· Delayed Price · Currency is ILS · Price in ILA5.90
+0.10 (1.72%)
Dec 22, 2024, 10:44 AM IDT
BioLineRx Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -19.92 | -60.61 | -24.95 | -27.05 | -30.02 | -25.45 | Upgrade
|
| Depreciation & Amortization | 2.86 | 1.33 | 0.65 | 0.7 | 0.93 | 0.94 | Upgrade
|
| Other Amortization | 0.06 | 0.06 | 0.17 | - | 0.59 | 0.47 | Upgrade
|
| Asset Writedown & Restructuring Costs | 6.7 | 6.7 | - | - | - | - | Upgrade
|
| Stock-Based Compensation | 2.22 | 2.32 | 2.25 | 1.5 | 1.27 | 1.76 | Upgrade
|
| Other Operating Activities | -15.49 | 12.4 | -5.6 | 1.82 | 5.3 | -4.72 | Upgrade
|
| Change in Accounts Receivable | -3.61 | -0.36 | - | - | - | - | Upgrade
|
| Change in Inventory | -2.19 | -1.95 | - | - | - | - | Upgrade
|
| Change in Accounts Payable | -3.12 | 5.51 | 1.89 | -0.56 | -1.72 | 3.22 | Upgrade
|
| Change in Unearned Revenue | 2.26 | 12.96 | - | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | -0.04 | -0.96 | -0.65 | 0.02 | 0.43 | 1.11 | Upgrade
|
| Operating Cash Flow | -30.27 | -22.61 | -26.24 | -23.57 | -23.21 | -22.67 | Upgrade
|
| Capital Expenditures | -0.08 | -0.12 | -0.13 | -0.1 | - | -0.07 | Upgrade
|
| Sale (Purchase) of Intangibles | -0 | -0.18 | -0.19 | - | - | -0.01 | Upgrade
|
| Investment in Securities | -2.1 | 1.74 | 4.32 | -38.13 | 16.67 | 5.33 | Upgrade
|
| Investing Cash Flow | -2.18 | 1.44 | 4.01 | -38.22 | 16.67 | 5.26 | Upgrade
|
| Long-Term Debt Issued | - | - | 9.13 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -1.99 | -3.05 | -3.57 | -3.36 | -1.1 | Upgrade
|
| Net Debt Issued (Repaid) | 15.52 | -1.99 | 6.07 | -3.57 | -3.36 | -1.1 | Upgrade
|
| Issuance of Common Stock | 17.99 | 17.04 | 14.36 | 61.32 | 21.22 | 20.3 | Upgrade
|
| Financing Cash Flow | 33.51 | 15.06 | 20.44 | 57.75 | 17.87 | 19.19 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.05 | -0.22 | -0.61 | 0.21 | 0.21 | 0.11 | Upgrade
|
| Net Cash Flow | 1.11 | -6.33 | -2.4 | -3.84 | 11.53 | 1.89 | Upgrade
|
| Free Cash Flow | -30.35 | -22.72 | -26.37 | -23.67 | -23.21 | -22.73 | Upgrade
|
| Free Cash Flow Margin | -138.00% | -473.42% | - | - | - | - | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.02 | -0.03 | -0.04 | -0.09 | -0.16 | Upgrade
|
| Cash Interest Paid | 0.36 | 1.11 | 0.59 | 0.68 | 0.99 | 1.2 | Upgrade
|
| Levered Free Cash Flow | -16.98 | -9.6 | -15.32 | -14.54 | -13.66 | -11.55 | Upgrade
|
| Unlevered Free Cash Flow | -14.68 | -8.26 | -14.2 | -13.92 | -12.74 | -10.15 | Upgrade
|
| Change in Net Working Capital | 2.34 | -15.2 | -1.27 | 0.54 | 1.29 | -4.32 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.